This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AUA 2024
APCCC 2024
EAU 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2018
ASCO GU 2018
Prostate Cancer
Bladder Cancer
Renal Cancer
Penile, Urethral, Testicular and Adrenal Cancers
Press
ASCO GU 2018 Renal Cancer
Viewing 22-41 of 68 articles
ASCO GU 2018: Conditional Survival and Landmark Analysis for Patients with Small Renal Masses Undergoing Active Surveillance at a Tertiary Care Center
ASCO GU 2018: Antibiotic Use and Outcomes with Systemic Therapy in Metastatic Renal Cell Carcinoma (mRCC)
ASCO GU 2018: Incidence and mortality of Renal Cell Carcinoma in the U.S.: A SEER-based Study Investigating Trends Over the Last Four Decades
ASCO GU 2018: Trends and Morbidity for Minimally Invasive Versus Open Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma
ASCO GU 2018: Renal Cell Carcinoma Primary Tumor Shrinkage on Vascular Endothelial Growth Factor Targeted Therapy - A Pooled Analysis
ASCO GU 2018: Association of Age and Sex with Mortality Following Adjuvant Therapy for Renal Cell Cancer: Subgroup Analysis of the ASSURE (E2805) Trial
ASCO GU 2018:Oncologic and Functional Follow-up After Renal Mass Treatment
ASCO GU 2018: Interpreting Data on Renal Function Preservation After Nephrectomy: Has the EORTC Trial Put the Issue to Rest?
ASCO GU 2018: Impact of Metastatic Local Treatment in the Strategy of Metastatic Renal Cell Carcinoma Including Stereotactic Radiotherapy, Surgery, and Radiofrequency in an Expert Center.
ASCO GU 2018: Assessing The Quality-adjusted Time Without Symptoms of Disease Progression or Toxicity (Q-TWiST) In Immuno-Oncology: An Application to Nivolumab vs. Everolimus in Previously Treated Advanced RCC
ASCO GU 2018: Comparing Cabozantinib Treatment for a Cohort of Patients with Metastatic Clear Cell RCC and Variant Histology RCC: A Retrospective Study
ASCO GU 2018: U-SMART: A Novel Scoring System of Preoperative Predictors to Stratify Oncologic Risk of Small Renal Mass
ASCO GU 2018: Can Health-Related Quality of Life Predict Conditional Survival in Metastatic RCC? Results from a Large Phase III Trial
ASCO GU 2018: Characterization of the Benefit-Risk Profile of Nivolumab + Ipilimumab Sunitinib for Treatment-Naïve Advanced RCC (Checkmate 214)
ASCO GU 2018: Outcomes of Patients with Metastatic Clear-Cell RCC Treated with Second-Line VEGFR-TKI After First-Line Immune Checkpoint Inhibitors
ASCO GU 2018: Outcomes of Metastatic Chromophobe Renal Cell Carcinoma with Sarcomatoid Features
ASCO GU 2018: Analysis of an Online Tool to Explore Evolving Practice Patterns in Renal Cell Carcinoma
ASCO GU 2018: Creation of a Tissue Expression Biomarker-augmented Prognostic Model for Patients with Metastatic Renal Cell Carcinoma
ASCO GU 2018: The Future of Immuno-Oncology in Renal Cell Carcinoma
ASCO GU 2018: Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: Past, Present, and Future
1
2
3
4
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free